ubscribing to the notion that the best defense is a good offense, Johnson & Johnson (JNJ) is appealing directly to large swaths of the public not to believe claims made by Pfizer (PFE) in a lawsuit that the health care giant used illegal tactics to protect a best-selling drug.

In a missive posted on its web site late last week and addressed to patients, doctors, insurers, and employers, J&J argued that Pfizer is, essentially, whining about an inability to successfully capture market share for its biosimilar version of Remicade, a blockbuster treatment for rheumatoid arthritis and other diseases.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • As I may have previously observed, the Pfizer approach seems mild compared to the J&J measures again Abbott for Humira, pre-AbbVie, some years ago. That is, at least, one person’s observation. I would be curious to see what “oii” (of happy memory) might think.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy